It is not medical advice and does not describe expected outcomes for any individual
therefore, OG has the potential to decrease sebum output.[32] Further, when evaluated in animal models, topical OG consistently reduced sebaceous gland size.[33] While this molecule was designed to inhibit sebum production following topical application, per Dermiras website, none of the primary endpoints for the trials directly evaluated sebum output or the appearance of oily skin
Side effects can be mild or severe, temporary, or permanent
Some insurance providers choose to only cover certain indications, like cardiovascular risk reduction
Interim pharmacokinetic and safety updates continue to support the Phase 2 profile, and researchers are closely watching for the larger, longer-duration data that will ultimately shape the regulatory trajectory for the molecule
Generally, normalization of hypercortisolism is associated with improvement of glucose metabolism, even though in some cases it may persist (100)